VivoSim Labs, formerly Organovo Holdings, focuses on non-animal liver toxicology prediction through its NAMkind™ platform, aiming to disrupt traditional preclinical drug testing paradigms. The company reported ongoing operating losses in its latest filings and is actively raising capital to support R&D and corporate activities. Its moat relies on early positioning in regulatory-driven alternatives to animal testing, but widespread market adoption and financial sustainability remain key risks. Monitoring collaboration growth, regulatory milestones, and cash runway will be critical for assessing progress.